Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a Study of OBP-801 in Advanced Solid Tumors
NCT02414516Phase 1Unknown
- Sponsor
- Oncolys BioPharma Inc.
- Start
- Mar 2015
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Spiruchostatin A in solid tumor, sponsored by Oncolys BioPharma Inc. Primary endpoint: Maximum Tolerated Dose at 6 weeks. Status: unknown.
02
Drugs
Spiruchostatin A
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02414516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02414516.